

JCO6 Rec'd PCT/PTO 20 SEP 2005

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

KURODA et al

Atty. Ref.: 1035-560

Serial No. 10/519,559

TC/A.U.: unassigned

Filed: December 28, 2004

Examiner: unassigned

For: HOLLOW NANOPARTICLES HAVING MODIFIED CYSTEINE
RESIDUE, AND DRUG USING THE HOLLOW NANOPARTICLES

* * * * *

September 20, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.

- ☒ Copies of U.S. Patent Publications are not required and are not attached.
- ☒ Listed foreign patent publications and other documents are enclosed.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.


The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached reference has been considered and made of record.

The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information referenced herein and attached hereto was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

KURODA et al
Serial No. 10/519,559

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 
Frank P. Presta
Reg. No. 19,828

FPP:cr
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.